Nomegestrol acetate
Suppliers
Names
[ CAS No. ]:
58652-20-3
[ Name ]:
Nomegestrol acetate
[Synonym ]:
[(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
EINECS 261-379-8
6-Methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate
Lutenyl
(17a)-17-Acetyl-6-methyl-3-oxoestra-4,6-dien-17-yl acetate
MFCD00941390
17-Acetoxy-6-methyl-19-norpregna-4,6-diene-3,20-dione
Nomegestrol acetate
Estra-4,6-dien-3-one, 17-acetyl-17-(acetyloxy)-6-methyl-, (17α)-
19-normegestrol acetate
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
507.3±50.0 °C at 760 mmHg
[ Molecular Formula ]:
C23H30O4
[ Molecular Weight ]:
370.482
[ Flash Point ]:
219.8±30.2 °C
[ Exact Mass ]:
370.214417
[ PSA ]:
60.44000
[ LogP ]:
3.34
[ Vapour Pressure ]:
0.0±1.3 mmHg at 25°C
[ Index of Refraction ]:
1.554
[ Storage condition ]:
2-8°C
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- RC8899200
- CHEMICAL NAME :
- 19-Norpregna-4,6-diene-3,20-dione, 17-alpha-hydroxy-6-methyl-, acetate
- CAS REGISTRY NUMBER :
- 58652-20-3
- LAST UPDATED :
- 199603
- DATA ITEMS CITED :
- 6
- MOLECULAR FORMULA :
- C23-H30-O4
- MOLECULAR WEIGHT :
- 370.53
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 1050 ug/kg/21D-I
- TOXIC EFFECTS :
- Endocrine - changes in luteinizing hormone Endocrine - estrogenic Endocrine - effect on menstrual cycle
- REFERENCE :
- BJOGAS British Journal of Obstetrics and Gynaecology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.82- 1975- Volume(issue)/page/year: 94,1199,1987
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 5 mg/kg
- SEX/DURATION :
- female 4 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - other measures of fertility
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,710,1983
Safety Information
[ Symbol ]:
GHS08, GHS09
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H361fd-H400
[ Precautionary Statements ]:
P280
[ Hazard Codes ]:
N
[ Risk Phrases ]:
63-50
[ Safety Phrases ]:
61
[ RIDADR ]:
UN 3077 9 / PGIII
[ RTECS ]:
RC8899200
Articles
J. Fam. Plann. Reprod. Health Care 39(3) , 211-6, (2013)
Initial oral contraceptive regimens were characterised by high doses of ethinylestradiol (EE) and a progestogen in a 21-day regimen that either included seven additional hormone-free tablets or simply...
Womens. Health (Lond. Engl.) 9(1) , 13-23, (2013)
Most combined oral contraceptive pills contain ethinyl estradiol (EE) with progestins. In order to minimize the pill's cardiovascular risks, the concept of using 17β-estradiol (E2), the endogenous est...
J. Steroid Biochem. Mol. Biol. 142 , 48-51, (2014)
• The “newer” progestogens have a high bioavailability. • The “newer” progestogens have a sufficient progestogenic effect. • The “newer” progestogens do not cause undue side effects. • The “newer” pro...